Fondaparinux
- TRADE NAME: Arixtra (Mylan)
- INDICATIONS: Prophylaxis of deep vein thrombosis
- CLASS: Anticoagulant (antithrombotic), Heparinoid
- HALF-LIFE: 17–21 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abciximab, Anagrelide, Anticoagulants, Cilostazol, Clopidogrel, Dabigatran, Dipyridamole, Eptifibatide, Nandrolone, Salicylates, Ticlopidine, Tirofiban
PREGNANCY CATEGORY: B
SPINAL/EPIDURAL HEMATOMAS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fondaparinux in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric